Cargando…
Type 1 diabetes and engineering enhanced islet transplantation
The development of new therapeutic approaches to treat type 1 diabetes mellitus (T1D) relies on the precise understanding and deciphering of insulin-secreting β-cell biology, as well as the mechanisms responsible for their autoimmune destruction. β-cell or islet transplantation is viewed as a potent...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science Publishers, B.V
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531713/ https://www.ncbi.nlm.nih.gov/pubmed/36002043 http://dx.doi.org/10.1016/j.addr.2022.114481 |
_version_ | 1784801959525482496 |
---|---|
author | Jeyagaran, Abiramy Lu, Chuan-en Zbinden, Aline Birkenfeld, Andreas L. Brucker, Sara Y. Layland, Shannon L. |
author_facet | Jeyagaran, Abiramy Lu, Chuan-en Zbinden, Aline Birkenfeld, Andreas L. Brucker, Sara Y. Layland, Shannon L. |
author_sort | Jeyagaran, Abiramy |
collection | PubMed |
description | The development of new therapeutic approaches to treat type 1 diabetes mellitus (T1D) relies on the precise understanding and deciphering of insulin-secreting β-cell biology, as well as the mechanisms responsible for their autoimmune destruction. β-cell or islet transplantation is viewed as a potential long-term therapy for the millions of patients with diabetes. To advance the field of insulin-secreting cell transplantation, two main research areas are currently investigated by the scientific community: (1) the identification of the developmental pathways that drive the differentiation of stem cells into insulin-producing cells, providing an inexhaustible source of cells; and (2) transplantation strategies and engineered transplants to provide protection and enhance the functionality of transplanted cells. In this review, we discuss the biology of pancreatic β-cells, pathology of T1D and current state of β-cell differentiation. We give a comprehensive view and discuss the different possibilities to engineer enhanced insulin-secreting cell/islet transplantation from a translational perspective. |
format | Online Article Text |
id | pubmed-9531713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Science Publishers, B.V |
record_format | MEDLINE/PubMed |
spelling | pubmed-95317132022-10-11 Type 1 diabetes and engineering enhanced islet transplantation Jeyagaran, Abiramy Lu, Chuan-en Zbinden, Aline Birkenfeld, Andreas L. Brucker, Sara Y. Layland, Shannon L. Adv Drug Deliv Rev Article The development of new therapeutic approaches to treat type 1 diabetes mellitus (T1D) relies on the precise understanding and deciphering of insulin-secreting β-cell biology, as well as the mechanisms responsible for their autoimmune destruction. β-cell or islet transplantation is viewed as a potential long-term therapy for the millions of patients with diabetes. To advance the field of insulin-secreting cell transplantation, two main research areas are currently investigated by the scientific community: (1) the identification of the developmental pathways that drive the differentiation of stem cells into insulin-producing cells, providing an inexhaustible source of cells; and (2) transplantation strategies and engineered transplants to provide protection and enhance the functionality of transplanted cells. In this review, we discuss the biology of pancreatic β-cells, pathology of T1D and current state of β-cell differentiation. We give a comprehensive view and discuss the different possibilities to engineer enhanced insulin-secreting cell/islet transplantation from a translational perspective. Elsevier Science Publishers, B.V 2022-10 /pmc/articles/PMC9531713/ /pubmed/36002043 http://dx.doi.org/10.1016/j.addr.2022.114481 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Jeyagaran, Abiramy Lu, Chuan-en Zbinden, Aline Birkenfeld, Andreas L. Brucker, Sara Y. Layland, Shannon L. Type 1 diabetes and engineering enhanced islet transplantation |
title | Type 1 diabetes and engineering enhanced islet transplantation |
title_full | Type 1 diabetes and engineering enhanced islet transplantation |
title_fullStr | Type 1 diabetes and engineering enhanced islet transplantation |
title_full_unstemmed | Type 1 diabetes and engineering enhanced islet transplantation |
title_short | Type 1 diabetes and engineering enhanced islet transplantation |
title_sort | type 1 diabetes and engineering enhanced islet transplantation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531713/ https://www.ncbi.nlm.nih.gov/pubmed/36002043 http://dx.doi.org/10.1016/j.addr.2022.114481 |
work_keys_str_mv | AT jeyagaranabiramy type1diabetesandengineeringenhancedislettransplantation AT luchuanen type1diabetesandengineeringenhancedislettransplantation AT zbindenaline type1diabetesandengineeringenhancedislettransplantation AT birkenfeldandreasl type1diabetesandengineeringenhancedislettransplantation AT bruckersaray type1diabetesandengineeringenhancedislettransplantation AT laylandshannonl type1diabetesandengineeringenhancedislettransplantation |